Medicenna Therapeutics appoints Richard Sutin, Angelos Georgakis to board

Medicenna Therapeutics (MDNAF) announces that Mr. Richard Sutin and Mr. Angelos Georgakis have been appointed, effective as of February 12, 2026, to the board of directors of the Company. Mr. Sutin and Mr. Georgakis’s appointments to the Board follow the retirement, effective as of February 12, 2026, of Ms. Karen Dawes, who has served on the Board since 2019, most recently as Chair of the Compensation Committee and as a member of the Audit Committee. Angelos Georgakis is a strategic advisor to biotech leaders and a long-term supporter of Medicenna. Richard Sutin provides corporate legal and ancillary business advisory services to early-stage businesses.